In the first-line setting, alectinib and brigatinib have exhibited advantages than crizotinib11–13 and were approved by FDA as the standard first-line treatment for NSCLC patients with ALK rearrangement. The gene discussed is ALK; the disease is non-small cell lung carcinoma.